Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy

European Journal of Endocrinology

Volumn 155, Issue 5, 2006, Pages 757-761

  Martos Moreno, Gabriel Á ^a   Barrios, Vicente ^a   Soriano Guillén, Leandro ^a   Argente, Jesús ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GHRELIN; INSULIN; INSULIN LISPRO; INTERLEUKIN 6; ISOPHANE INSULIN; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ANTHROPOMETRY; ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; PREDICTION; PREPUBERTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ACYLATION; ADIPONECTIN; BODY MASS INDEX; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN; INTERLEUKIN-6; LEPTIN; MALE; PEPTIDE HORMONES; PROSPECTIVE STUDIES; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845270779     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02273     Document Type: Article

References (27)

1. Sinha A, Formica C, Tsalamandris C, Panagiotopoulos S, Hendrich E, DeLuise M, Seeman E & Jerums G. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. Diabetic Medicine 1996 13 40-46.
2. Kershaw EE & Flier JS. Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology and Metabolism 2004 89 2548-2556.
3. Meier U & Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clincal chemical aspects of leptin, ghrelin, adiponectin, and resitin. Clinical Chemistry 2004 50 1511-1525.
4. Berg AH, Combs TP, Du X, Brownlee M & Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 2001 7 947-953.
5. Lihn AS, Pedersen SB & Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews 2005 6 13-21.
6. Reinehr T, Roth C, Menke T & Andler W. Adiponectin before and after weight loss in obese children. Journal of Clinical Endocrinology and Metabolism 2004 89 3790-3794.
7. Jain SK, Kannan K, Lim G, Matthews-Greer J, McVie R & Bocchini JA Jr. Elevated blood interleukin-6 levels n hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care 2003 26 2139-2143.
8. Hoffman WH, Burek CL, Waller JL, Fisher LE, Khichi M & Mellick LB. Cytokine response to diabetic ketoacidosis and its treatment. Clinical Immunology 2003 108 175-181.
9. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup, A & Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. American Journal of Physiology. Endocrinology and Metabolism 2003 285 E527-E533.
10. Argente J, Barrios V, Chowen JA, Sinha MK & Considine RV. Leptin plasma levels in healthy Spanish children and adolescents, children with obesity, and adolescents with anorexia nervosa and bulimia nervosa. Journal of Pediatrics 1997 131 833-838.
11. Soriano-Guillen L, Barrios V, Chowen JA, Sánchez I, Vila S, Quero J & Argente J. Ghrelin levels from fetal life through early adulthood: relationship with endocrine and metabolic and anthropometric measures. Journal of Pediatrics 2004 144 30-35.
12. Soriano-Guillen L, Barrios V, Lechuga-Sancho, A, Chowen JA & Argente J. Response of circulating ghrelin levels to insulin therapy in children with newly diagnosed type 1 diabetes mellitus. Pediatric Research 2004 55 830-835.
13. Soriano-Guillen L, Barrios V, Martos G, Chowen JA, Campos-Barros A & Argente J. Effect of oral glucose administration on ghrelin levels in obese children. European Journal of Endocrinology 2004 151 119-121.
14. Celi F, Bini V, Papi F, Santilli E, Ferretti A, Mencacci M, Berioli MG, De Giorgi G & Falorni A. Circulating acylated and total ghrelin and galanin in children with insulin-treated type 1 diabetes: relationship to insulin therapy, metabolic control and pubertal development. Clinical Endocrinology (Oxford) 2005 63 139-145.
15. Gauna C, Delhanty PJ, Hofland LJ, Janssen JA, Broglio E Ross RJ, Ghigo E & van der Lely AJ. Ghrelin stimulates, whereas desoctanoyl gharelin inhibits, glucose output by primary hepatocytes. Journal of Clinical Endocrinology and Metabolism 2005 90 1055-1060.
16. Hernández M, Castellet J, Narvaiza JL, Rincón JM, Ruiz I & Sánchez E. In Curvas y tablas de crecimiento. Instituto de Investigación sobre Crecimiento y Desarrollo. Fundación Faustino Orbegozo. Madrid: Editorial Garsi, 1988.
17. Perez-Bravo F, Santos JL, Carrasco E, Calvillan M, Albala C, Puig-Domingo M, Piquer S & De Leiva A. Transmission of high-risk HLA-DQB1 alleles in Chilean type 1 diabetic patients and their parents: stratification by the presence of ICA or GAD65 autoantibodies. Autoimmunity 2001 33 285-291.
18. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, Abribat T, Van Der Lely AJ & Ghigo E. Non-acylated ghrelin. counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. Journal of Clinical Endocrinology and Metabolism 2004 89 3062-3065.
19. Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld P, Hofland LJ, Broglio F, Ghigo E & van der Lely AJ. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. Journal of Clinical Endocrinology and Metabolism 2004 89 5035-5042.
20. Carlson MG & Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993 42 1700-1707.
21. Schaffler A, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J & Zietz B. Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2. Experimental and Clinical Endocrinology and Diabetes 2004 112 383-389.
22. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S & Andersen O. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. American Journal of Physiology. Endocrinology and Metabolism 2003 285 E1072-E1080.
23. Wolfe BE, Jimerson DC, Orlova C & Mantzoros CS. Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clinical Endocrinology 2004 61 332-338.
24. Tsuchida A, Yamauchi T & Kadowaki T. Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin. Journal of Pharmacological Sciences 2005 97 164-170.
25. Lee JH, Bullen JW Jr, Stoyneva VL & Mantzoros CS. Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia. American Journal of Physiology, Endocrinology and Metabolism 2005 288 E625-E632.
26. Lee JH, Chan JL, Yinnnakouris N, Kontogianni M, Estrada E, Seip R, Orlova C & Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. Journal of Clinical Endocrinology and Metabolism 2003 88 4848-4856.
27. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q & Considine RV. Serum resistin (FM3) protein is increased in obese humans. Journal of Clinical Endocrinology and Metabolism 2003 88 5452-5455.